Market Place
Sourcing Support
Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline
27 Apr 2023 //
PR NEWSWIRE
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML
20 Apr 2023 //
BUSINESSWIRE
Jazz Pharma Secures Eight Additional Provincial Reimbursements for Vyxeos
08 Mar 2023 //
PRESS RELEASE
Teva`s troubled plant seen to create injectable drug shortages
24 May 2022 //
FIERCEPHARMA
BDR launches India’s first generic Midostaurin (MSTARIN) to treat Leukemia
07 Dec 2021 //
EXPRESS PHARMA
Jazz Announces FDA Approval of Additional Indication for Vyxeos®
30 Mar 2021 //
PRNEWSWIRE
Final NICE green light for Pfizer’s Mylotarg
15 Nov 2018 //
PHARMA TIMES
NICE recommends Jazz Pharmaceuticals’ Vyxeos to treat AML
10 Nov 2018 //
PHARMACEUTICAL TECH
NICE recommends Vyxeos for specific secondary AML
08 Nov 2018 //
BIOSPECTRUM
Vyxeos® Receives Marketing Authorisation in the European Union for AML
27 Aug 2018 //
PR NEWSWIRE
Jazz hiring 100-plus sales reps for new narcolepsy and AML launches
20 Aug 2018 //
FIERCE PHARMA
Journal of Clinical Oncology publishes pivotal Ph3 data for Jazz Pharms` Vyxeos
19 Jul 2018 //
PR NEWSWIRE
CAR-T therapies leap towards EU approval
02 Jul 2018 //
PHARMATIMES
European Regulators Make Decisions on Several Companies’ Drugs
26 Feb 2018 //
BIOSPACE
Price of Teva`s Generic Drug to Treat Wilson’s Disease Sparks Outrage
26 Feb 2018 //
BIOSPACE
National Comprehensive Cancer Network® adds Jazz Pharmaceuticals` Vyxeos™
08 Feb 2018 //
PR NEWSWIRE
Speedy review for Jazz’ high-risk AML chemo
06 Nov 2017 //
PHARMA TIMES
FDA panel backs Pfizer`s once-pulled AML med Mylotarg
11 Jul 2017 //
FIERCE PHARMA
Jazz Announces FDA Acceptance of NDA for VYXEOS™
31 May 2017 //
PR NEWSWIRE
Diplomat Now Dispensing RYDAPT® (Midostaurin) for Acute Myeloid Leukemia
18 May 2017 //
PR NEWSWIRE
Sayre Therapeutics Announces DaunoXome Named Patient Program in India
07 Oct 2016 //
PHARMATIMES
Celator Pharmaceuticals Presented PIII Trial Results in Acute Myeloid Leukemia
06 Jun 2016 //
PR NEWSWIRE
Celator® Pharma Announces Positive Data for VYXEOS™ in FLT3-ITD Mutated AML
18 Apr 2016 //
PR NEWSWIRE
Celator Announces Ph3 Trial for VYXEOS™in Patients with High-Risk Acute Leukemia
14 Mar 2016 //
PR NEWSWIRE
Celator Announces Participation in Cardiff University Clinical Trial in Adults
11 Jan 2016 //
PR NEWS WIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.